Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study

SIMPLE SUMMARY: Everolimus is an oral drug used in patients with advanced hormone receptor positive, HER2 negative breast cancer. In this study based on a national French real-world cohort of more than 22,000 patients, we sought to evaluate the impact of everolimus on overall survival. Using statist...

Descripción completa

Detalles Bibliográficos
Autores principales: François-Martin, Hélène, Lardy-Cléaud, Audrey, Pistilli, Barbara, Levy, Christelle, Diéras, Véronique, Frenel, Jean-Sébastien, Guiu, Séverine, Mouret-Reynier, Marie-Ange, Mailliez, Audrey, Eymard, Jean-Christophe, Petit, Thierry, Ung, Mony, Desmoulins, Isabelle, Augereau, Paule, Bachelot, Thomas, Uwer, Lionel, Debled, Marc, Ferrero, Jean-Marc, Clatot, Florian, Goncalves, Anthony, Chevrot, Michael, Chabaud, Sylvie, Cottu, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954606/
https://www.ncbi.nlm.nih.gov/pubmed/36831532
http://dx.doi.org/10.3390/cancers15041191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954606/
https://www.ncbi.nlm.nih.gov/pubmed/36831532
http://dx.doi.org/10.3390/cancers15041191

Ejemplares similares